A Randomized, Open-Label, Multicenter, Phase II Trial Evaluating the Safety and Activity of Pinatuzumab Vedotin (DCDT2980S) in Combination with Rituximab or Polatuzumab Vedotin (DCDS4501A) in Combination with Rituximab and a Non-Randomized Phase Ib/II Evaluation or Polatuzumab Vedotin in Combination with Obinutuzumab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Description: 

The primary objectives of this study are to assess the safety and tolerability of the combination of DCDT2980S and rituximab administered to patients with relapsed or refractory follicular NHL and DLBCL.

Study Number: 

PH 230212

Phase: 
II
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01691898

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.